Semaglutide

Semaglutide is a medicine used to treat type 2 diabetes. It is also used for long-term weight loss in people with obesity. For some people with heart disease who are overweight, semaglutide can help lower the risk of serious heart problems. This medicine works like a natural hormone in the body called GLP-1, which helps control blood sugar and appetite. Semaglutide can be given as a shot or taken as a pill. It is sold under different brand names: Ozempic and Rybelsus for diabetes, and Wegovy for weight loss.

The most common side effects include nausea, vomiting, diarrhea, stomach pain, and constipation. In March 2026, the FDA approved a new higher-dose shot called Wegovy HD (7.2 mg), which helped people lose about 21% of their body weight on average . About one-third of patients lost 25% or more of their starting weight .

This new dose became available in April 2026 . Around the same time, the European Union approved a version of semaglutide called Kayshild to treat a serious liver disease known as MASH (metabolic dysfunction-associated steatohepatitis) in patients with moderate to advanced liver scarring .

Followingly in April 2026, the FDA tentatively approved the first generic version of injectable semaglutide, though it cannot be sold yet due to patent protections . By March 2026, nearly 8 out of every 100 prescriptions in the U.S. were for GLP-1 medicines like semaglutide, with demand for weight-loss versions growing quickly .

FDA-Approved Uses

1. Type 2 Diabetes (T2DM)
Approved as adjunct to diet and exercise to improve glycemic control in adults with T2DM. Approved under Ozempic (injection) and Rybelsus (oral tablet).

2. Cardiovascular Risk Reduction
Approved (Ozempic/Rybelsus) to reduce risk of MACE (cardiovascular death, non-fatal MI, or non-fatal stroke) in adults with T2DM and established CV disease or elevated risk.

3. Chronic Kidney Disease (CKD)
Approved (Ozempic) to reduce risk of sustained eGFR decline, ESKD, and CV death in adults with T2DM and CKD.

4. Chronic Weight Management
Approved (Wegovy injection and Wegovy pill) for long-term weight reduction in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

5. MASH (approved August 2025)
Expanded Wegovy indication to include noncirrhotic metabolic-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.

6. Oral Weight Management (approved December 2025)
Wegovy pill 25 mg approved — first oral GLP-1 for weight management.

7. Wegovy HD (approved March 2026)
Higher-dose 7.2 mg injectable approved for weight loss and long-term weight maintenance.

Trade Names in USA and Manufacturers

– Ozempic (injection 0.5 mg, 1 mg, 2 mg) — Novo Nordisk
– Rybelsus (oral tablet 3 mg, 7 mg, 14 mg) — Novo Nordisk
[FDA accepted ‘Ozempic’ as brand name for oral formulation Q1 2026; relabeling Q2 2026]
– Wegovy (injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) — Novo Nordisk
– Wegovy HD (injection 7.2 mg) — Novo Nordisk [approved March 2026]
– Wegovy pill (oral tablet 25 mg) — Novo Nordisk [approved December 2025]
– Generic semaglutide injection: Tentative FDA approval to Apotex Corp / Orbicular Pharmaceutical Technologies — not yet commercially launched as of May 2026

Dosage

Injectable Wegovy (Weight Management) — Weekly Subcutaneous:
Weeks 1–4: 0.25 mg/week (starting dose)
Weeks 5–8: 0.5 mg/week
Weeks 9–12: 1.0 mg/week
Weeks 13–16: 1.7 mg/week
Week 17+: 2.4 mg/week (maintenance)
[Wegovy HD 7.2 mg is a separately approved higher-dose option]

Ozempic (Type 2 Diabetes) — Weekly Subcutaneous:
Weeks 1–4: 0.25 mg/week (initiation)
Week 5+: 0.5 mg/week
If needed: increase to 1 mg, then 2 mg/week

Rybelsus (Type 2 Diabetes) — Once Daily Oral:
Month 1: 3 mg/day
Month 2: 7 mg/day
Month 3+: 14 mg/day (maintenance)
[Take on empty stomach ≥30 min before food/drink/other meds]

Wegovy Pill (Weight Management) — Once Daily Oral:
Titrate over 12 weeks to 25 mg/day maintenance

Pricing

Brand-name list prices (2026):
– Wegovy injection (all doses): ~$1,349/month
– Ozempic injection (all doses): ~$1,027–$1,028/month
– Rybelsus tablets: ~$998/month
[Note: Novo Nordisk announced $675/month list price for all three, effective Jan 1, 2027]

NovoCare Pharmacy self-pay (no insurance):
– Wegovy injectable pen: $349/month ($199 new patients, first 2 months)
– Wegovy HD pen: $399/month
– Wegovy pill 25 mg: $149–$299/month
– Ozempic pen: $349–$499/month ($199 new patients, first 2 months)
– Rybelsus: $149/month

With commercial insurance + savings card:
– As low as $25/month (eligible patients; capped at $100/month savings)

Coverage by Insurance Type

1. ACA Marketplace
– For Diabetes (Ozempic/Rybelsus): Often covered
– For Weight Loss (Wegovy): Rarely covered

2. Employer Insurance
– For Diabetes: Widely covered
– For Weight Loss: ~43% of large employers

3. Medicare Part D
– For Diabetes/CKD/CV risk (Ozempic): Covered
– For Weight Loss (Wegovy): NOT covered by statute

4. Medicaid
– For Diabetes: Most states
– For Weight Loss: Varies by state
[CMS BALANCE Model: opt-in states ~$245/month]

5. TRICARE (Military)
– For Diabetes: Covered
– For Weight Loss: Covered with prior auth criteria

Tips

– If denied for weight loss, ask doctor if you qualify under diabetes, cardiovascular risk, or CKD — those have broader coverage.
– Use NovoCare direct self-pay: Wegovy starts $349/month ($199 new patients).
– Commercial insurance + Novo Nordisk savings card = as low as $25/month.
– Medicare covers Ozempic for diabetes/CKD, not Wegovy for weight loss — confirm with Part D plan.
– Compounded semaglutide: FDA shortage resolved 2025; 503A/503B compounding of copies prohibited April–May 2025. Verify any compounding source for current FDA compliance.
– Prior authorization is near-universal; have provider document BMI, comorbidities, and prior treatment attempts.

Side Effects of Semaglutide

Common (from clinical trials):
– Gastrointestinal: Nausea, vomiting, diarrhea, constipation, abdominal pain — most frequent; typically decrease over time.
– Decreased appetite: Commonly reported; contributes to weight loss.
– Headache and fatigue.

Serious/Less Common:
– Acute pancreatitis: Observed in GLP-1 users; discontinue if suspected.
– Gallbladder disorders (cholelithiasis, cholecystitis).
– Diabetic retinopathy complications: Especially with rapid glucose improvement in patients with pre-existing retinopathy.
– Acute kidney injury: Secondary to GI-related volume depletion.
– Hypoglycemia: When combined with insulin or sulfonylureas.
– Serious hypersensitivity: Anaphylaxis and angioedema (rare).
– Pulmonary aspiration: Reported during general anesthesia/deep sedation.
– Altered skin sensation (Wegovy HD 7.2 mg): More frequent at higher dose; generally self-resolving.
– Thyroid C-cell tumors: Seen in rodents; human relevance undetermined. Boxed warning.

Contraindications

– Personal or family history of medullary thyroid carcinoma (MTC).
– Multiple endocrine neoplasia syndrome type 2 (MEN 2).
– Known serious hypersensitivity to semaglutide or any excipient.
– Not approved for Type 1 diabetes.
– Do not co-administer with other semaglutide products or other GLP-1 receptor agonists.
– Not studied in patients with history of pancreatitis; use with caution.
– Not studied in patients with severe gastroparesis or severe GI disease.

Pharmacology

Semaglutide is a synthetic GLP-1 receptor agonist with ~94% structural homology to native human GLP-1. It is a 31-amino acid peptide modified with a C18 fatty diacid chain via a linker to lysine at position 26, enabling albumin binding that extends plasma half-life to ~7 days (allowing once-weekly dosing). The oral formulation (Rybelsus) is co-formulated with absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) to enable gastric mucosal absorption. Available as subcutaneous injection and oral tablet.

Mechanism of Action

Semaglutide selectively binds to and activates the GLP-1 receptor (G-protein coupled receptor):
– Stimulates glucose-dependent insulin secretion from pancreatic beta cells (only when blood glucose is elevated — reduces hypoglycemia risk).
– Suppresses glucagon secretion from pancreatic alpha cells when blood glucose is high.
– Slows gastric emptying, reducing postprandial glucose excursions.
– Acts on hypothalamic receptors to reduce appetite and caloric intake.
– At higher doses (Wegovy), appetite suppression and reduced caloric intake produce significant sustained weight loss.

Result Claims By Different Companies

Novo Nordisk (based on published clinical trial results):
– SUSTAIN trials (T2D): Significant HbA1c and body weight reductions vs. placebo and comparators including sitagliptin, exenatide, and insulin glargine.
– SELECT trial (CV outcomes): 20% reduction in risk of MACE in adults with pre-existing CV disease who were overweight or obese (NEJM 2023).
– FLOW trial (kidney): 24% reduction in composite kidney/CV outcome in adults with T2D and CKD.
– STEP trials (obesity): ~15% average body weight reduction at 68 weeks with Wegovy 2.4 mg vs. placebo.
– OASIS 4 trial (oral Wegovy): 13.6% mean weight loss at 64 weeks (treatment-policy analysis); 16.6% with full adherence.
– Wegovy HD (7.2 mg): Additional average weight reduction vs. 2.4 mg dose; consistent safety profile.
– ESSENCE trial (MASH): Resolution of MASH with improvement in liver fibrosis — supported August 2025 FDA approval.

Disclaimer

This content about “Semaglutide” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.